查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1654677

全球乳癌筛检与诊断技术市场 - 2025 至 2033 年

Global Breast Cancer Screening and Diagnostic Techniques Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 168 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球乳癌筛检和诊断技术市场规模达到 68 亿美元，预计到 2033 年将达到 117 亿美元，2025-2033 年预测期内的复合年增长率为 6.3%。

乳癌筛检和诊断技术是指在症状出现之前或在出现症状的个体中用于检测、诊断和评估乳癌的一系列医疗程序、测试和技术。这些方法旨在儘早发现乳癌，并提高成功治疗和存活的机会。

筛检包括检查没有任何明显症状的人是否有乳癌迹象，目的是在治疗最有效时儘早发现癌症。一旦透过筛检发现潜在异常，就会使用诊断技术来确认是否是癌症并评估其类型和程度。

受乳癌发病率上升、技术进步以及对早期检测重要性的认识不断提高等因素推动，乳癌筛检和诊断技术市场的需求正在不断增长。例如，粉红丝带运动和乳癌宣传月（十月）等倡议大大提高了全球意识，鼓励女性定期接受检查。

市场动态：

驱动因素与约束因素

乳癌发生率上升

乳癌盛行率的上升极大地推动了乳癌筛检和诊断技术市场的成长，并预计将在预测期内推动市场的发展。乳癌是目前全球最常见的癌症，由于人口老化、生活方式改变和诊断能力提高等因素，其盛行率持续增加。这直接影响对早期检测和诊断技术的需求。

例如，根据世界卫生组织 (WHO) 的数据，2022 年有 230 万名女性被诊断出罹患乳癌。乳癌影响青春期后各年龄层的女性，但其发生率在后期有所上升。此外，根据乳癌组织的数据，到 2024 年，美国约有 310,720 名女性被诊断出患有侵袭性乳癌，其中 16% 是年龄在 50 岁以下的女性。病例数量的不断增长推动了对全面筛检和诊断工具的需求，以便儘早发现和治疗。

由于生活方式的改变和遗传倾向导致乳癌发生率上升，对预防筛检和诊断技术的需求也日益增长。有乳癌家族史或基因突变（如 BRCA1/2）的女性罹患乳癌的风险更高。基因检测正变得越来越普及，高风险女性对此的需求也越来越大。

人工智慧诊断的准确性和标准化有限

人工智慧（AI）融入乳癌筛检和诊断具有重大的前景。然而，准确性有限和缺乏标准化等挑战阻碍了其广泛应用。在非多样化资料集上训练的人工智慧模型可能无法很好地推广到不同人群。例如，使用某一人口统计资料开发的人工智慧系统在应用于另一个人口统计资料时可能会表现不佳，导致诊断结果不一致。这种多变性可能导致假阳性和假阴性，从而破坏对人工智慧诊断的信任。

人工智慧演算法可能难以识别特定形式的乳癌，例如间隔癌（IC），这种癌症具有侵袭性并且通常无法透过标准筛检方法发现。儘管人们努力提高检测能力，但 IC 仍占已检测到的乳癌的约 30%，而 AI 在提高其检测能力方面的成功率有限。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的片段
  • 技术片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 乳癌发生率上升
    • 限制
      • 人工智慧诊断的准确性和标准化有限
    • 机会
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • 新兴创业公司和关键创新者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：乳癌筛检和诊断技术市场（按产品类型）

  • 筛检设备
  • 诊断试剂盒和检测试剂
  • 切片设备
  • 软体和基于人工智慧的检测工具

第 6 章：乳癌筛检与诊断技术市场（按技术）

  • 影像技术
    • 乳房X光检查
    • 超音波
    • 电脑断层扫描
    • 磁振造影
    • 其他的
  • 切片技术
  • 基因和生物标记检测

第 7 章：乳癌筛检和诊断技术市场（按最终用户划分）

  • 医院
  • 专科诊所
  • 诊断影像中心
  • 研究实验室
  • 其他的

第 8 章：乳癌筛检和诊断技术市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • GE HealthCare
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 关键进展
    • SWOT 分析
  • Hologic, Inc.
  • Koninklijke Philips NV
  • Siemens Healthineers AG
  • FUJIFILM Holdings Corporation
  • Myriad Genetics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • QIAGEN NV
  • Bio-Rad Laboratories, Inc.

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MI4115

The global breast cancer screening and diagnostic techniques market reached US$ 6.8 billion in 2024 and is expected to reach US$ 11.7 billion by 2033, growing at a CAGR of 6.3% during the forecast period 2025-2033.

Breast cancer screening and diagnostic techniques refer to a range of medical procedures, tests, and technologies used to detect, diagnose, and evaluate breast cancer, either before symptoms appear or in individuals presenting with symptoms. These methods aim to identify breast cancer in its earliest stages, improving the chances of successful treatment and survival.

Screening involves checking for signs of breast cancer in people who do not have any noticeable symptoms, with the goal of detecting cancers early when treatment is most effective. Once a potential abnormality is identified through screening, diagnostic techniques are used to confirm whether it is cancer and to assess its type and extent.

The breast cancer screening and diagnostic techniques market is experiencing increasing demand, driven by factors such as a rising incidence of breast cancer, advances in technology, and growing awareness of the importance of early detection. For instance, initiatives such as the Pink Ribbon Campaign and Breast Cancer Awareness Month (October) have significantly increased global awareness, encouraging women to undergo regular screening.

Market Dynamics: Drivers & Restraints

Rising prevalence of breast cancer

The rising prevalence of breast cancer is significantly driving the growth of the breast cancer screening and diagnostic techniques market and is expected to drive the market over the forecast period. Breast cancer is now the most commonly diagnosed cancer worldwide, with its prevalence continuously increasing due to factors like population aging, lifestyle changes, and improved diagnostic capabilities. This directly impacts the demand for early detection and diagnostic technologies.

For instance, according to the World Health Organization (WHO), in 2022, 2.3 million women were diagnosed with breast cancer. Breast cancer affects women of all ages after puberty, although the incidence rises later in life. Additionally, according to the Breast Cancer Organization, in 2024, approximately 310,720 women diagnosed with invasive breast cancer, 16% of which will be in women younger than 50 years of age in the United States. The growing number of cases drives the need for comprehensive screening and diagnostic tools for early detection and treatment.

As lifestyle changes and genetic predispositions contribute to the rising incidence of breast cancer, the need for preventive screening and diagnostic techniques grows. Women with a family history of breast cancer or genetic mutations (like BRCA1/2) are at a much higher risk. Genetic testing, which is becoming more widely available, is in high demand for women at elevated risk.

Limited accuracy & standardization in AI-driven diagnostics

The integration of Artificial Intelligence (AI) into breast cancer screening and diagnostics holds significant promise. However, challenges related to limited accuracy and lack of standardization are impeding its widespread adoption. AI models trained on non-diverse datasets may not generalize well across varied populations. For instance, an AI system developed using data from one demographic may underperform when applied to another, leading to inconsistent diagnostic outcomes. This variability can result in both false positives and false negatives, undermining trust in AI-driven diagnostics.

AI algorithms may struggle to identify specific forms of breast cancer, such as interval cancers (ICs), which are aggressive and often elude standard screening methods. Despite efforts to enhance detection, ICs account for approximately 30% of detected breast cancers, and AI's success in improving their detection has been limited.

Segment Analysis

The global breast cancer screening and diagnostic techniques market is segmented based on product type, technology, end-user and region.

Product Type:

The imaging techniques segment is expected to dominate the breast cancer screening and diagnostic techniques market share

Mammography remains the gold standard in breast cancer screening, which significantly drives the demand for imaging technologies in this market. Mammography is highly effective in detecting early-stage breast cancer, particularly in women over 40. The technique allows radiologists to identify suspicious lumps, microcalcifications, or other abnormalities that could indicate cancer.

For instance, in November 2024, GE HealthCare launched its new Pristina Via mammography system which is designed to enhance the breast screening experience for both technologists and patients. Pristina enhancements will help decrease repetitive tasks and improve processes, allowing mammography techs to concentrate on delivering quality and personalized care.

Ultrasound is frequently used as a supplementary imaging technique alongside mammography to further assess abnormalities or to guide biopsies. Ultrasound is particularly beneficial for women with dense breast tissue, where mammograms might miss certain cancers. It is also effective in distinguishing between solid tumors and benign cysts, reducing unnecessary biopsies.

For instance, in December 2024, the novel ultrasound measurement and monitoring technology launched for early breast cancer detection. This Sona's technology enables women to proactively monitor their breast health before they are old enough to access a mammogram. It enables healthcare providers to provide timely personalised screening through simple, safe and low-cost access to breast density information, which is currently limited by a woman's age and use of traditional mammograms.

Geographical Analysis

North America is expected to hold a significant position in the breast cancer screening and diagnostic techniques market share

The rising number of breast cancer cases in North America especially in the United States and Canada is a significant driver for the increased demand for screening and diagnostic techniques in the region. According to the Breast Cancer Organization, 310,720 women diagnosed with invasive breast cancer. This high incidence directly translates to a growing need for screening and diagnostic technologies.

Additionally, according to the Canadian Cancer Society, in 2022, an estimated 28,600 Canadian women diagnosed with breast cancer. Breast cancer is responsible for around 25% of new cancer diagnoses and among Canadian women. One in every eight women is anticipated to acquire breast cancer over her lifetime. This contributes to the high demand for early detection technologies.

Awareness campaigns and high public knowledge about the importance of early breast cancer detection have significantly increased demand for screening and diagnostic tests in North America. For instance, October is recognized as Breast Cancer Awareness Month in North America, during which public campaigns increase awareness about the importance of routine screening and early detection, driving higher participation in screening programs.

Asia-Pacific is growing at the fastest pace in the breast cancer screening and diagnostic techniques market

Many Asia-Pacific countries are investing significantly in improving healthcare infrastructure, which is directly impacting the adoption of advanced breast cancer screening and diagnostic techniques. Countries like China, India, Japan, and South Korea are making substantial investments in healthcare infrastructure. For instance, China and India has implemented national cancer screening programs that increase access to mammography and ultrasound technologies in rural areas.

The rise of private hospitals and healthcare facilities in countries like India and Southeast Asia has significantly increased access to advanced breast cancer diagnostic tools. Major private hospitals in cities like Mumbai and Singapore now offer state-of-the-art diagnostic services, including 3D mammography, MRI, and AI-powered diagnostics. For instance, in December 2024, Deepak Phenolics Limited unveiled a transformative initiative with the launch of a Mobile Mammography Van (MMV) designed to detect breast cancer at its early stages.

The rising awareness about breast cancer and increasing governmental support in the APAC region especially in India and China are pivotal to the growth of the screening and diagnostic market. For instance, in January 2025, Fujifilm India launched brand film Maa's fight through my eyes under the series Stories of More Smiles, highlighting breast cancer awareness initiative

Competitive Landscape

The major global players in the breast cancer screening and diagnostic techniques market include GE HealthCare, Hologic, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, FUJIFILM Holdings Corporation, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Danaher Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Breast Cancer Screening and Diagnostic Techniques market report delivers a detailed analysis with 62 key tables, more than 55 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Technology
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Breast Cancer
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Accuracy & Standardization in AI-Driven Diagnostics
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Breast Cancer Screening and Diagnostic Techniques Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Screening Devices*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Diagnostic Kits & Assays
  • 5.4. Biopsy Devices
  • 5.5. Software & AI-based Detection Tools

6. Breast Cancer Screening and Diagnostic Techniques Market, By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Imaging Techniques*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Mammography
    • 6.2.4. Ultrasound
    • 6.2.5. Computed Tomography
    • 6.2.6. Magnetic Resonance Imaging
    • 6.2.7. Others
  • 6.3. Biopsy Techniques
  • 6.4. Genetic and Biomarker Testing

7. Breast Cancer Screening and Diagnostic Techniques Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Diagnostic Imaging Centers
  • 7.5. Research Laboratories
  • 7.6. Others

8. Breast Cancer Screening and Diagnostic Techniques Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. GE HealthCare*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Hologic, Inc.
  • 10.3. Koninklijke Philips N.V.
  • 10.4. Siemens Healthineers AG
  • 10.5. FUJIFILM Holdings Corporation
  • 10.6. Myriad Genetics, Inc.
  • 10.7. F. Hoffmann-La Roche Ltd
  • 10.8. Danaher Corporation
  • 10.9. QIAGEN N.V.
  • 10.10. Bio-Rad Laboratories, Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us